Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Inclusion criteria

Stage I-III Criteria-

• Patients aged 18 years or over who had had a macroscopically curative resection for gastric adenocarcinoma.
• Absence of metastatic disease evident from:

• physical examination
• the most recent chest X-ray
• abdominal CT or ultrasound scan
• Life expectancy of at least 3 months
• WHO performance status of 0 to 1
• Written informed consent given

Stage IV Criteria-

• Patients aged 18 years or over with Stage IV gastric cancer: carcinoma with the primary tumour invading the adjacent structures and/or involvement of more than 15 regional lymph nodes and/or distant metastases
• Life expectancy of at least 3 months
• WHO performance status of 0 to 2
• Written informed consent given

Exclusion criteria

• History of other malignant disease except non-melanomatous skin cancer or in situ carcinoma of the uterine cervix Recurrent gastric cancer following previous surgery Presence of metastatic disease: peritoneal deposits or involved lymph nodes outside the limit of resection
• Previous use, concomitant use or anticipated use in the period of the study, of any anti-cancer therapies
• Concomitant use of immunosuppressants, including systemic (ie oral or injected) corticosteroids
• Females who were pregnant, planning to become pregnant or lactating
• Patients who were taking part in another study involving an investigational or licensed drug or device in the three months preceding enrolment or during this study
• Previous G17DT treatment
• Haematological indicators:

• Haemoglobin <10.0g/dl
• White blood cell count <4.0 x 109/l
• Platelets <100 x 109/l